Perceptions of Pap Screening in a Context of HPV Vaccination

Cervical cancer is second most common cancer affecting women and the third most common cause of cancer mortality in women worldwide (1). Cervical cancer is caused by infection with the sexually transmitted human papillomavirus (HPV), of which there are over 120 types (2). It has been estimated that over 80% of sexually active females will be infected with HPV in their lifetimes, most in their mid to late teens, 20s, and early 30s (3). While infection is often harmless and clears spontaneously, persistent infection with high-risk types can lead to the development of cervical cancer (4).

[1]  J. Denollet,et al.  Theory of Planned Behavior , 2015 .

[2]  D. Gertig,et al.  Cervical screening rates for women vaccinated against human papillomavirus , 2014, The Medical journal of Australia.

[3]  Basil Donovan,et al.  Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. , 2014, Vaccine.

[4]  R. Jaiyesimi,et al.  Human papillomavirus vaccination in adolescence , 2013, Perspectives in Public Health.

[5]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012 .

[6]  J. Wardle,et al.  Exploring age differences in reasons for nonattendance for cervical screening: a qualitative study , 2012, BJOG : an international journal of obstetrics and gynaecology.

[7]  M. Stanley,et al.  Analyses of human papillomavirus genotypes and viral loads in anogenital warts , 2011, Journal of medical virology.

[8]  J. Leask,et al.  National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program. , 2010, Sexual health.

[9]  S. Garland,et al.  "Is cancer contagious?": Australian adolescent girls and their parents: making the most of limited information about HPV and HPV vaccination. , 2010, Vaccine.

[10]  Subhashini Jagu,et al.  Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection , 2009, Immunology and cell biology.

[11]  N. Letourneau,et al.  Cervical cancer screening practices among university women. , 2008, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[12]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[13]  M. Stanley Human papillomavirus (HPV) vaccines: prospects for eradicating cervical cancer , 2004, Journal of Family Planning and Reproductive Health Care.

[14]  H. Stein,et al.  Esophageal squamous cell cancer in patients with head and neck cancer: Prevalence of human papillomavirus DNA sequences , 2004, International journal of cancer.

[15]  M. Weinstein,et al.  A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine , 2003, International journal of cancer.

[16]  Gopal K Singh,et al.  Sociodemographic predictors of pap test receipt, currency and knowledge among Australian women. , 2002, Preventive medicine.

[17]  R. Glasgow,et al.  Barriers to mammography and pap smear screening among women who recently had neither, one or both types of screening , 2000, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[18]  B. Thomadsen,et al.  Biomedical Engineering Online Review of "brachytherapy Physics, Second Edition" Edited Book Details , 2022 .

[19]  M. Patton Qualitative research and evaluation methods , 1980 .